U.S. FDA Action Drives Ranbaxy Into Red; Company May Buyout Manufacturing Sites To Recover Lost Ground

MUMBAI - India's largest drug maker Ranbaxy suffered heavy losses during its third quarter primarily due to U.S. FDA action in September that clamped an import ban on over 30 of its products